Article

Tissue of Origin Test Results May Have Treatment Implications

Author(s):

Brielle Benyon

Tests like these are growing increasingly important, as TOO results lead to treatment changes about 65 percent of the time and a site treatment change about 35 percent of the time, according to Cancer Genetics.

A new gene expression test, called the Tissue of Origin (TOO) test, designed to analyze a tumor’s genomic information, received 510(k) clearance from the Food and Drug Administration (FDA)

The TOO test, developed by Cancer Genetics, Inc., assesses 2,000 individual genes that are found within about 90 percent of all solid tumors, including thyroid, breast, lung, pancreatic, gastric, colorectal, liver, bladder, kidney, ovarian, testicular and prostate cancers, as well as non-Hodgkin lymphoma, melanoma and sarcoma. The test then uses this information to identify a tumor’s origin, which can help to classify it as metastatic, poorly differentiated or undifferentiated.

“This 510(k) clearance represents an important milestone toward our goal of gaining broad adoption of the test,” John A. (Jay) Roberts, interim chief executive officer and chief operations officer of Cancer Genetics, said in a press release.

Currently, TOO is Medicare-reimbursed, and, according to the release, is the only FDA-cleared test of its kind. Tests like these are growing increasingly important, as TOO results lead to treatment changes about 65 percent of the time and a site treatment change about 35 percent of the time, according to Cancer Genetics.

“Despite increasing excellence in the diagnostic workup for malignancies, there are approximately 150,000 newly diagnosed cases of metastatic cancer with unclear diagnosis in the US and Europe each year. This includes the subset of patients with cancer of unknown primary (CUP) and of uncertain origin. Increasingly complex algorithms and testing associated with a diagnostic workup also means that many challenging cases have insufficient amount of sample material for analysis,” Rita Shaknovich, chief medical officer of CGI, said.

The most recent version of TOO has some differences from an earlier version. The test has new labeling reagents and a higher accuracy rate and shorter workflow. But this did not compromise precision and reproducibility. These new features can continue to help health care teams make more informed treatment decisions.

“Our TOO test represents a unique offering with the ability to add significant value to the continuum of care for cancer patients and greatly enhance our biopharma partners’ development efforts,” Roberts said.

Under this clearance, also known as Premarket Approval (PMA), a manufacturer must demonstrate to the FDA that it is substantially equivalent (as safe and effective) to a device already on the market. This occurs within 90 days before the company plans to put the device on the market. In the meantime, the FDA rules whether there is currently another similar or identical device that is already in use, which determines whether the company can manufacture the device.

Related Videos
Image of woman with blonde hair.
Image of woman with brown hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of a woman with tied back hair, wearing pearl earrings.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a doctor with dark curly hair and rectangular glasses.
Image of a woman wearing a red tank top.
Image of a woman with a brown hair tied into a bun.
Image of Annie Bond.
Related Content
Image of a page in a book that says "pancreatic cancer."
November 22nd 2024

‘One Tree Hill’ Actor Dies of Cancer, ‘Jeopardy!’ Contestant Reveals Diagnosis and More

Alex Biese Ashley Chan
From the deaths of actor Paul Teal and Chicago Bulls player Bob Love to a contestant on “Jeopardy!” revealing his colon cancer diagnosis, here’s what’s happening in the oncology space this week.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Illustration of woman with blonde hair.
November 20th 2024

What Patients with Breast Cancer Need to Know About Lymphedema Risk

Alex Biese
CURE® spoke with a physical therapist specializing in oncology to find out more about this condition some patients with cancer are at risk for.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Illustration of a woman with long blonde hair in a pony tail.
November 18th 2024

How Do You Survive Cancer Survivorship?

Jessica Bolz
As a four-time cancer survivor, I can tell you that survivorship means many things to each survivor.
Illustration of a person's pancreas, indicating cancer.
November 15th 2024

Quincy Jones Died of Cancer, Dwayne Johnson Connects with a Fan with Cancer and More

Alex Biese
From producer Quincy Jones’ death from pancreatic cancer to an inspiring moment between The Rock and a fan at a store, here’s what’s happening in the cancer space this week.